Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain ProgramGlobeNewsWire • 10/13/26
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential MilestonesGlobeNewsWire • 08/12/26
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and AstellasGlobeNewsWire • 06/23/26
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for StakeholdersGlobeNewsWire • 06/08/26
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/14/26
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial ResultsGlobeNewsWire • 05/14/26
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)GlobeNewsWire • 04/30/26
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsGlobeNewsWire • 03/30/26
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings CallGlobeNewsWire • 03/19/26
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseGlobeNewsWire • 03/09/26
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026GlobeNewsWire • 02/03/26
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten OfferingGlobeNewsWire • 02/03/26
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseGlobeNewsWire • 12/18/25
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyGlobeNewsWire • 12/02/25
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry DiseaseGlobeNewsWire • 11/21/25
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/06/25
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/06/25
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025GlobeNewsWire • 09/04/25